Abo Bibliothek: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Erscheint 6 Ausgaben pro Jahr

ISSN Druckformat: 0743-4863

ISSN Online: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Possible Role of Epidermal Growth Factor Receptors in the Therapy of Pancreatic Cancer

Volumen 28, Ausgabe 4, 2011, pp. 293-356
DOI: 10.1615/CritRevTherDrugCarrierSyst.v28.i4.10
Get accessGet access

ABSTRAKT

Pancreatic cancer is considered an 'orphan' cancer because of its relative low incidence. Unfortunately, even with early diagnosis, mortality rates are high and it ranks eighth in the worldwide ranking of deaths due to cancer. The administration of chemotherapeutic agents for the treatment of advanced disease has failed, and current research focuses on the understanding of molecular pathways in order to investigate the role of targeted therapy. It has been known that the development and the progression of pancreatic cancer are caused by the activation of oncogenes, the inactivation of tumor suppressor genes, and the deregulation of many signaling pathways of various growth factors, among which the epidermal growth factor receptor (EGFR) plays an important role. Growth factor receptors and their ligands not only regulate normal cell processes, but have also been identified as key regulators of human cancer formation. EGFR has been found to be expressed and altered in pancreatic cancer and clearly plays a significant role in tumor development and progression, including cell proliferation, regulation of apoptotic cell death, angiogenesis, and metastatic spread. The amplitude and kinetics of growth factor signaling are determined mainly by a highly regulated endocytic process that sorts and directs activated receptors to degradation in lysosomes. Therefore, EGFR is a legitimate therapeutic target. The aim of this review is to outline the endocytic escape of EGFRs in cancer with special attention towards recent advances in various approaches adopted for EGFR targeting.

REFERENZIERT VON
  1. Liu Ke, Qin Cheng-Kun, Wang Zhi-Yi, Liu Su-Xia, Cui Xian-Ping, Zhang Dong-Yuan, Expression of Tumor Necrosis Factor-alpha-induced Protein 8 in Pancreas Tissues and its Correlation with Epithelial Growth Factor Receptor Levels, Asian Pacific Journal of Cancer Prevention, 13, 3, 2012. Crossref

  2. Farhana Lulu, Dawson Marcia I., Murshed Farhan, Das Jayanta K., Rishi Arun K., Fontana Joseph A., Hoheisel Jörg D., Upregulation of miR-150* and miR-630 Induces Apoptosis in Pancreatic Cancer Cells by Targeting IGF-1R, PLoS ONE, 8, 5, 2013. Crossref

  3. Hofheinz Ralf-Dieter, Segaert Siegfried, Safont María José, Demonty Gaston, Prenen Hans, Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors, Critical Reviews in Oncology/Hematology, 114, 2017. Crossref

  4. Gupta Swati, Pathak Yashwant, Gupta Manish K., Vyas Suresh P., RETRACTED ARTICLE: Nanoscale drug delivery strategies for therapy of ovarian cancer: conventional vs targeted, Artificial Cells, Nanomedicine, and Biotechnology, 47, 1, 2019. Crossref

  5. Ren Xiaoxin, Li Yixian, Nishimura Christopher, Zang Xingxing, Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities, Genes & Diseases, 9, 5, 2022. Crossref

Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen Preise und Aborichtlinien Begell House Kontakt Language English 中文 Русский Português German French Spain